

# Daniel SerÃ³n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8164746/publications.pdf>

Version: 2024-02-01

63  
papers

3,457  
citations

279798

23  
h-index

144013

57  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3146  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of Obtaining an Extra Biobank Kidney Biopsy Core. <i>Journal of Clinical Medicine</i> , 2022, 11, 1459.	2.4	0
2	Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1364-1370.	2.9	30
3	Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 482-491.	2.9	12
4	Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study. <i>Transplant Infectious Disease</i> , 2021, 23, e13494.	1.7	6
5	Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism. <i>Journal of Clinical Medicine</i> , 2021, 10, 141.	2.4	7
6	Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation. <i>Transplantation</i> , 2021, 105, 648-659.	1.0	22
7	Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.7	23
8	Kidney transplantation and COVID-19 renal and patient prognosis. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i21-i29.	2.9	32
9	Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2021, 10, 1934.	2.4	9
10	A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2174.	2.4	2
11	COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab. <i>Nefrologia</i> , 2021, 41, 354-355.	0.4	3
12	Clinical Relevance of Corticosteroid Withdrawal on Graft Histological Lesions in Low-Immunological-Risk Kidney Transplant Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2005.	2.4	6
13	Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model. <i>Molecular and Cellular Endocrinology</i> , 2021, 529, 111263.	3.2	7
14	COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 452-459.	2.0	2
15	Surgeon preimplantation macroscopic graft appraisal improves risk stratification of deceased kidney donors: a prospective study. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	4
16	Kidney function changes and their relation with the progression of cerebral small vessel disease and cognitive decline. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116635.	0.6	16
17	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020, 104, 911-922.	1.0	172
18	Biopsia renal transyugular. La alternativa a la biopsia percutánea en pacientes de alto riesgo. <i>Nefrologia</i> , 2020, 40, 634-639.	0.4	3

#	ARTICLE	IF	CITATIONS
19	A Rejection Gene Expression Score in Indication and Surveillance Biopsies Is Associated with Graft Outcome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8237.	4.1	1
20	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell <sup>+</sup> and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2318-2331.	4.7	437
21	Derivation and external validation of the SIMPLICITY score as a simple immune-based risk score to predict infection in kidney transplant recipients. <i>Kidney International</i> , 2020, 98, 1031-1043.	5.2	5
22	Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020, 71, 2375-2385.	5.8	29
23	A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis. <i>Scientific Reports</i> , 2020, 10, 1159.	3.3	10
24	Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2245.	4.1	3
25	Revisiting Experimental Models of Diabetic Nephropathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3587.	4.1	46
26	The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2019, 8, 864.	2.4	17
27	Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000845.	2.8	24
28	Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study. <i>Journal of Clinical Virology</i> , 2019, 110, 45-50.	3.1	2
29	Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study. <i>Transplant International</i> , 2019, 32, 313-322.	1.6	22
30	Kidney allograft subclinical rejection modulates systemic inflammation measured by C-reactive protein at 1 year after transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13196.	1.6	3
31	Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 927-935.	4.7	134
32	Evaluación de la empatía en donante vivo de riñón. <i>Nefrología</i> , 2018, 38, 570-572.	0.4	0
33	Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus. <i>Kidney International Reports</i> , 2018, 3, 1304-1315.	0.8	47
34	Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies. <i>Transplantation</i> , 2017, 101, 1410-1415.	1.0	38
35	Calidad de vida relacionada con la salud en el trasplante renal: seguimiento longitudinal a 2 años. <i>Medicina Clínica</i> , 2017, 149, 114-118.	0.6	12
36	Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. <i>Transplant International</i> , 2017, 30, 1119-1131.	1.6	10

#	ARTICLE	IF	CITATIONS
37	Alfabetizaci3n en salud y enfermedad renal cr3nica. <i>Nefrologia</i> , 2017, 37, 115-117.	0.4	5
38	Fascin-1 is released from proximal tubular cells in response to calcineurin inhibitors (CNIs) and correlates with isometric vacuolization in kidney transplanted patients. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 4173-4183.	0.0	3
39	Inflammation and Atherosclerosis Are Associated With Hypertension in Kidney Transplant Recipients. <i>Journal of Clinical Hypertension</i> , 2015, 17, 963-969.	2.0	16
40	Renal Biopsy in Type 2 Diabetic Patients. <i>Journal of Clinical Medicine</i> , 2015, 4, 998-1009.	2.4	55
41	The Interplay between Inflammation and Fibrosis in Kidney Transplantation. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	49
42	The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. <i>Kidney International</i> , 2014, 85, 1161-1168.	5.2	126
43	Innate immunity in renal transplantation: The role of mannose-binding lectin. <i>Transplantation Reviews</i> , 2014, 28, 21-25.	2.9	12
44	Gene expression signature of tolerance and lymphocyte subsets in stable renal transplants: Results of a cross-sectional study. <i>Transplant Immunology</i> , 2014, 31, 11-16.	1.2	26
45	Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 213-220.	0.7	82
46	Early Subclinical Rejection as a Risk Factor for Late Chronic Humoral Rejection. <i>Transplantation</i> , 2012, 93, 41-46.	1.0	92
47	Histology and proteinuria after renal transplantation. <i>Transplantation Reviews</i> , 2012, 26, 20-26.	2.9	10
48	Subclinical rejection in renal transplants is associated with low serum mannose-binding lectin levels. <i>Kidney International Supplements</i> , 2011, 1, 36-39.	14.2	6
49	Intragraft Expression of the IL-10 Gene Is Up-Regulated in Renal Protocol Biopsies with Early Interstitial Fibrosis, Tubular Atrophy, and Subclinical Rejection. <i>American Journal of Pathology</i> , 2010, 176, 1696-1704.	3.8	20
50	Low Serum Mannose-Binding Lectin as a Risk Factor for New Onset Diabetes Mellitus After Renal Transplantation. <i>Transplantation</i> , 2009, 88, 272-278.	1.0	26
51	Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. <i>Kidney International</i> , 2008, 74, S94-S99.	5.2	46
52	Management of cardiovascular risk in patients receiving calcineurin inhibitorsâ€”a case report. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, iii30-iii33.	0.7	4
53	Increased cardiovascular risk profile and mortality in kidney allograft recipients with postâ€transplant diabetes mellitus in Spain. <i>Clinical Transplantation</i> , 2006, 20, 650-658.	1.6	23
54	Risk factors associated with the deterioration of renal function after kidney transplantation. <i>Kidney International</i> , 2005, 68, S113-S117.	5.2	18

#	ARTICLE	IF	CITATIONS
55	Early post-transplant renal allograft function between 1990 and 1998 in Spain. Nephrology Dialysis Transplantation, 2004, 19, iii43-iii46.	0.7	1
56	Baseline Immunosuppression is Associated with Histological Findings in Early Protocol Biopsies. Transplantation, 2004, 78, 1064-1068.	1.0	50
57	Antibody-Mediated Rejection Criteria - an Addition to the Banff <sup>TM</sup> 97 Classification of Renal Allograft Rejection. American Journal of Transplantation, 2003, 3, 708-714.	4.7	960
58	Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transplant International, 2003, 16, 820-827.	1.6	40
59	Late renal allograft failure between 1990 and 1998 in Spain: A changing scenario <sup>1</sup> . Transplantation, 2003, 76, 1588-1594.	1.0	49
60	International Variation in Histologic Grading Is Large, and Persistent Feedback Does Not Improve Reproducibility. American Journal of Surgical Pathology, 2003, 27, 805-810.	3.7	189
61	Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney International, 2002, 61, 727-733.	5.2	109
62	Early protocol renal allograft biopsies and graft outcome. Kidney International, 1997, 51, 310-316.	5.2	223
63	Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. Transplant International, 1993, 6, 236-238.	1.6	21